

Jacqueline L Olin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8957556/publications.pdf>

Version: 2024-02-01

39
papers

472
citations

759190

12
h-index

713444

21
g-index

39
all docs

39
docs citations

39
times ranked

722
citing authors

#	ARTICLE	IF	CITATIONS
1	Triple Negative Breast Cancer: A Brief Review of its Characteristics and Treatment Options. <i>Journal of Pharmacy Practice</i> , 2012, 25, 319-323.	1.0	92
2	Glucagon-Like Peptide-1 Analog and Insulin Combination Therapy in the Management of Adults with Type 2 Diabetes Mellitus. <i>Annals of Pharmacotherapy</i> , 2010, 44, 1294-1300.	1.9	37
3	3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: A therapeutic controversy. <i>Journal of Clinical Lipidology</i> , 2011, 5, 450-459.	1.5	35
4	Possible Valacyclovir-Related Neurotoxicity and Aseptic Meningitis. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1814-1817.	1.9	26
5	Paradoxical Bronchoconstriction with Albuterol Administered by Metered-Dose Inhaler and Nebulizer Solution. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1924-1927.	1.9	26
6	A Module on Death and Dying to Develop Empathy in Student Pharmacists. <i>American Journal of Pharmaceutical Education</i> , 2011, 75, 71.	2.1	23
7	Aromatase Inhibitors in Breast Cancer Prevention. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1605-1610.	1.9	23
8	Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet for HIV-1 Infection Treatment. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1671-1677.	1.9	22
9	Possible kratom-induced hepatomegaly: A case report. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2018, 58, 561-563.	1.5	19
10	Boceprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C. <i>Pharmacotherapy</i> , 2012, 32, 173-190.	2.6	18
11	Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy. <i>Annals of Pharmacotherapy</i> , 2012, 46, 240-247.	1.9	15
12	Tiotropium: An inhaled anticholinergic for chronic obstructive pulmonary disease. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 1263-1269.	1.0	13
13	Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy. <i>Annals of Pharmacotherapy</i> , 2019, 53, 812-832.	1.9	13
14	Risk of cancer associated with the use of angiotensin II-receptor blockers. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 2139-2146.	1.0	12
15	Instruments for evaluating medication use and prescribing in older adults. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2014, 54, 530-537.	1.5	12
16	Amphotericin B-Associated Hyperbilirubinemia: Case Report and Review of the Literature. <i>Pharmacotherapy</i> , 2006, 26, 1011-1017.	2.6	11
17	Prospective Measurement of a Problem-Based Learning Course Sequence. <i>American Journal of Pharmaceutical Education</i> , 2012, 76, 179.	2.1	9
18	Formulary Forum: Fesoterodine for the Treatment of Overactive Bladder. <i>Annals of Pharmacotherapy</i> , 2009, 43, 1992-2000.	1.9	8

#	ARTICLE	IF	CITATIONS
19	Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C. <i>Pharmacotherapy</i> , 2011, 31, 951-974.	2.6	8
20	Computer-based clinical simulation cases in oncology pharmacotherapy: Student perceptions from two campuses. <i>Currents in Pharmacy Teaching and Learning</i> , 2015, 7, 157-162.	1.0	8
21	Key Articles and Guidelines Relative to Treatment of Patients with Acute Coronary Syndromes. <i>Pharmacotherapy</i> , 2004, 24, 105-144.	2.6	7
22	Delayed Presentation of Hepatocellular Liver Injury After Nintedanib Administration. <i>American Journal of Therapeutics</i> , 2017, 24, e107-e108.	0.9	6
23	Alectinib for advanced ALK-positive non-small-cell lung cancer. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 515-522.	1.0	6
24	Baclofen-induced encephalopathy in an older patient with stage 2 chronic kidney disease. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2015, 55, 117-118.	1.5	4
25	Multidisciplinary approach to optimizing antibiotic prophylaxis of surgical-site infections. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 2312-2314.	1.0	3
26	ASHP-HOPA guidelines on the roles and responsibilities of the pharmacy technician in ambulatory oncology pharmacy. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1304-1311.	1.0	3
27	Experience with nesiritide at a community hospital. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 1337-1338.	1.0	2
28	Pomalidomide for the management of refractory multiple myeloma. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 1443-1448.	1.0	2
29	Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 517-524.	0.9	2
30	Pulmonary Edema and Possible Pneumonitis Associated with Celecoxib. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1086-1086.	1.9	1
31	Pharmacotherapy of High-Altitude Illness. <i>American Journal of Lifestyle Medicine</i> , 2007, 1, 129-141.	1.9	1
32	Communication between the pharmacy and the emergency department to facilitate alteplase delivery for patients with stroke. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 2022-2028.	1.0	1
33	Assessing Adherence to Insulin Initiation Recommendations at a Suburban Family Medicine Clinic. <i>American Journal of Therapeutics</i> , 2016, 23, e1542-e1546.	0.9	1
34	Expanded Basal Insulin Options for Type 2 Diabetes Mellitus. <i>Journal for Nurse Practitioners</i> , 2017, 13, 210-215.	0.8	1
35	Impact of Initial eGlycemic Management System Dosing Strategy on Time to Target Blood Glucose Range. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 242-250.	2.2	1
36	Publication rates of hematology/oncology abstracts presented at major pharmacy association meetings. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 582-587.	0.9	1

#	ARTICLE	IF	CITATIONS
37	Introduction: Cardiovascular Therapeutics. <i>Journal of Pharmacy Practice</i> , 2009, 22, 133-134.	1.0	0
38	Experience with Tolvaptan for Euvolemic and Hypervolemic Hyponatremia in the Acute Care Setting. <i>Hospital Pharmacy</i> , 2015, 50, 380-385.	1.0	0
39	Characterization of clinical pharmacist and hospitalist collaborative relationships. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 1413-1422.	1.0	0